Range
28.34 - 29.45
Vol / Avg.
91.4K/333K
Div / Yield
-
52 Wk
9.62 - 45
Mkt Cap
701.9M
Payout Ratio
-
Open
28.77
P/E
-
EPS
-0.56
Shares
24.4M
Outstanding
24.4M
Total Float
-
Benzinga - 6 days ago
Benzinga - May 10, 2021, 7:21AM
Benzinga - Apr 20, 2021, 8:18AM
Benzinga - Apr 20, 2021, 7:51AM
Benzinga - Apr 20, 2021, 6:44AM
Benzinga - Mar 11, 2021, 6:31AM
Benzinga - Feb 18, 2021, 8:40AM
Benzinga - Feb 11, 2021, 7:18AM
Benzinga - Feb 10, 2021, 12:03PM
Benzinga - Feb 10, 2021, 6:15AM
Benzinga - Feb 10, 2021, 5:54AM
Benzinga - Feb 9, 2021, 4:01PM
Benzinga - Feb 9, 2021, 3:31PM
Benzinga - Feb 9, 2021, 10:58AM
Benzinga - Feb 9, 2021, 10:44AM
Benzinga - Feb 9, 2021, 10:25AM
Benzinga - Feb 9, 2021, 6:38AM
Benzinga - Jan 26, 2021, 6:21AM
load more
Sector: Health Care.Industry: Biotechnology
KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates through the region of United States.

Earnings

see more
Q1 2022Est.ActualSurprise
EPS
(EXPECTED)2021-09-13
REV
Q4 2021Est.ActualSurprise
EPS
(EXPECTED)2021-06-30
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
KALVKalVista Pharmaceuticals-0.55%701.9M

KalVista Pharmaceuticals Frequently Asked Questions

Q

How do I buy KalVista Pharmaceuticals (KALV) stock?

A

You can purchase shares of KalVista Pharmaceuticals (NASDAQ: KALV) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are KalVista Pharmaceuticals's (KALV) competitors?

A

Other companies in KalVista Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Orchard Therapeutics (NASDAQ:ORTX), TCR2 Therapeutics (NASDAQ:TCRR), Sesen Bio (NASDAQ:SESN) and Adaptimmune Therapeutics (NASDAQ:ADAP).

Q

What is the target price for KalVista Pharmaceuticals (KALV) stock?

A

The latest price target for KalVista Pharmaceuticals (NASDAQ: KALV) was reported by Roth Capital on February 18, 2021. The analyst firm set a price target for 55.00 expecting KALV to rise to within 12 months (a possible 91.37% upside). 6 analyst firms have reported ratings in the last year.

Q

Current Stock Price for KalVista Pharmaceuticals (KALV)?

A

The stock price for KalVista Pharmaceuticals (NASDAQ: KALV) is $28.74 last updated Fri Jun 11 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does KalVista Pharmaceuticals (KALV) pay a dividend?

A

There are no upcoming dividends for KalVista Pharmaceuticals.

Q

When is KalVista Pharmaceuticals (NASDAQ:KALV) reporting earnings?

A
KalVista Pharmaceuticals’s Q1 earnings are confirmed for after-market on September 13, 2021.
Q

Is KalVista Pharmaceuticals (KALV) going to split?

A

There is no upcoming split for KalVista Pharmaceuticals.

Q

What sector and industry does KalVista Pharmaceuticals (KALV) operate in?

A

KalVista Pharmaceuticals is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.